The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
Official Title: An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)
Study ID: NCT01557777
Brief Summary: Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).
Detailed Description: This is an open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Site Reference ID/Investigator# 74036, La Jolla, California, United States
Site Reference ID/Investigator# 74035, Los Angeles, California, United States
Site Reference ID/Investigator# 74038, Pleasant Hill, California, United States
Site Reference ID/Investigator# 74039, Santa Maria, California, United States
Site Reference ID/Investigator# 74033, Bethesda, Maryland, United States
Site Reference ID/Investigator# 79201, Coburg, , Australia
Site Reference ID/Investigator# 78993, Greenslopes, , Australia
Site Reference ID/Investigator# 77860, Afula, , Israel
Site Reference ID/Investigator# 77637, Rechovot, , Israel
Site Reference ID/Investigator# 77413, Gdansk, , Poland
Site Reference ID/Investigator# 79203, Ivano-Frankivsk, , Ukraine
Site Reference ID/Investigator# 79205, Khmelnitsky, , Ukraine
Site Reference ID/Investigator# 79202, Kyiv, , Ukraine
Site Reference ID/Investigator# 79204, Lviv, , Ukraine
Site Reference ID/Investigator# 79206, Poltava, , Ukraine
Name: Mack Mabry, MD
Affiliation: AbbVie
Role: STUDY_DIRECTOR